Lacerol Retard (Diltiazem Hydrochloride)

Diltiazem blocks L‑type calcium channels in cardiac and vascular smooth muscle, reducing calcium influx. This decreases myocardial contractility and slows conduction through the atrioventricular node, while causing peripheral vasodilation, together lowering blood pressure and alleviating angina.

The dosage of Lacerol Retard is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength and frequency, which may be adjusted during therapy to achieve optimal blood pressure control or angina relief.

Safety of diltiazem during pregnancy and lactation has not been definitively established; it is classified as Category C in many regions. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions are made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacerol Retard (diltiazem) is a non‑dihydropyridine calcium channel blocker, offering both vasodilatory and negative‑chronotropic effects, unlike dihydropyridine agents such as amlodipine which primarily cause vasodilation. This dual action makes diltiazem useful for hypertension, angina, and atrial fibrillation rate control, whereas other classes may be preferred for isolated blood pressure reduction.

Lacerol Retard tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect them from moisture, direct sunlight, and excessive heat to maintain stability and potency throughout the shelf life.

Lacerol Retard is taken orally, usually once daily with or without food, as directed by the prescribing healthcare professional. The extended‑release formulation provides a gradual release of diltiazem over several hours, supporting consistent blood pressure control and angina relief.

Serious adverse events, though uncommon, can include severe bradycardia, hypotension, heart block, hepatic dysfunction, and life‑threatening allergic reactions such as Stevens‑Johnson syndrome. Patients should be monitored for these signs, and immediate medical attention is required if they occur.

Lacerol Retard is contraindicated in patients with known hypersensitivity to diltiazem or other calcium channel blockers, those with severe hypotension, sick sinus syndrome, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with acute myocardial infarction where its use may be harmful. Consultation with a physician is essential before initiating therapy.